Abstract
The brilliant geneticist, William Bateson, a formidable English experimentalist, was the first to recognize the nature of the “inborn” in Archibald Garrod’s errors of metabolism. Bateson’s advice to young scientists: “Treasure your exceptions!” summarizes much of the vigorous empiricism associated with the study of rare disorders.
The first inborn error of metabolism to be so recognized was alkaptonuria, and it is only recently that a proper understanding of this condition as a disease, rather than a biochemical curiosity, has emerged. Abnormal excretion of the reactive tyrosine metabolite, homogentisic acid, not only provides a tangible biomarker of alkaptonuria, but also a focus for detailed mechanistic understanding.
Currently, there is no proven treatment for alkaptonuria but emergence of orphan drug legislation internationally has promoted the licensing of nitisinone (Orfadin™) for an equally rare disorder of tyrosine metabolism – hereditary tyrosinaemia type 1. Nitisinone, a triketone competitive inhibitor of a proximal step leading to the formation of homogentisic acid, has potent therapeutic effects in hereditary tyrosinemia and rapidly ameliorates the primary biochemical abnormality in patients with alkaptonuria.
Here, we discuss the context in which nitisinone should be further explored for the treatment of alkaptonuria. This exceptional disease is a paradigm case, which opens up unusual opportunities for basic and applied research. In modern times, it also shows how the conflation of orphan drug legislation and the emerging power and commitment of patient organizations can synergize effectively to advance basic research and therapeutic development in ultra-orphan diseases.
Competing interests: None declared.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Nitisinone: 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1-3-dione-2-2-nitro-4-trifluoromethylbenzoyl cyclohexane-1-3-dione.
References
Anikster Y, Nyhan WL, Gahl WA (1998) NTBC and alkaptonuria. Am J Hum Genet 63:920–921
Bacon F (1620) Francis Bacon: the new Organon, or true directions for the interpretation of nature (Novum Organum). In: Jardine L, Silverthorne M (eds) (2000) Aphorisms, Book II, Chap. 29. Cambridge University Press, Cambridge, pp 102–221
Bateson W (1894) Materials for the study of variation, treated with especial regard to discontinuity in the origin of species. Macmillan, London, pp 85–86
Bateson W (1908) The methods and scope of genetics, Inaugural Lecture delivered 23 Oct 1908. Cambridge University Press, Cambridge
Bateson W (1913) Mendel’s principles of heredity, Chaps 4, 5 and 12. Cambridge University Press, Cambridge, pp. 77–87, 88–106, 212–216, 221
Beadle GW (1958) Genes and chemical reactions in Neurospora. In: Nobel Lectures including presentation speeches and laureates’ biographies. Physiology or Medicine, 1942–1962. Elsevier, Amsterdam, pp 587–597
Beadle GW, Ephrussi B (1937) Development of eye colors in Drosophila: diffusible substances and their inter-relations. Genetics 22:76–86
Boncinelli E (1997) Homeobox genes and disease. Curr Opin Genet Dev 7:331–337
Braun MM, Farag-El-Massah S, Xu K, Coté TR (2010) Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 9:519–522
Buckley BM (2008) Clinical trials of orphan medicines. Lancet 371:2051–2055
Chakrapani A, Holme E (2006) Disorders of tyrosine metabolism. In: Fernandes S, van den Berghe W (eds) Inborn metabolic diseases, diagnosis and treatment, 4th edn. Springer, Berlin, pp 233–243
Dietz HC (2010) New therapeutic approaches to mendelian disorders. N Engl J Med 363:852–863
Dolgin E (2010) Big pharma moves from ‘blockbusters’ to ‘niche busters’. Nat Med 16:837
European Committee for Orphan Medicinal Products (2011) European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov 10:341–349
Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D, Renedo M, Fernandez-Ruiz E, Penalva MA, Rodriguez de Cordoba S (1996) The molecular basis of alkaptonuria. Nat Genet 14:19–24. http://www.findakure.org/contact_us.php. Accessed 31 May 2011
Følling A (1934) Über Ausscheidung von Phenylbrenztraubensäure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillität. Hoppe-Seyler’s Zeitschrift Fuer Physiologische Chemie 227:169–176
Garrod AE (1901) About alkaptonuria. Lancet 2:1484–1486
Garrod AE (1902) The incidence of alkaptonuria: a study in chemical individuality. Lancet 2:1616–1620
Garrod AE (1909) Inborn errors of metabolism; the Croonian Lectures delivered before the Royal College of Physicians of London, in June, 1908. Henry Frowde, Hodder and Stoughton, Oxford University Press, London
Garrod AE (1924) The debt of science to medicine, Harveian oration, before the Royal College of Physicians on St Luke’s Day 1924. Clarendon, Oxford University, 30p
Garrod A (1928) The lessons of rare maladies: the Annual Oration delivered before the Medical Society of London on May 21st 1928. Lancet 211:1055–1060
Garrod AE (1931) The inborn factors in disease. Clarendon, Oxford University, London, p 65
Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA (2009) Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 96:20–26
Haffner ME (2006) Adopting orphan drugs – two dozen years of treating rare diseases. N Engl J Med 354:445–447
Harper PS (2005) William Bateson, human genetics and medicine. Hum Genet 118:141–151
Ingelfinger JR, Drazen JM (2011) Patient organisations and research on rare diseases. N Engl J Med 364:1670–1671
Introne WJ, Perry MB, Troendle J, Tsilou E, Kayser MA, Suwannarat P, O’Brien KE, Bryant J, Sachdev V, Reynolds JC, Moylan E, Bernardini I, Gahl WA (2011) A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab, E-pub, May, 6
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type 1 by inhibition of 4-hyroxyphenylpyruvate dioxygenase. Lancet 340:813–817
Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL (1998) From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis 42:498–506
Mannoni A, Selvi E, Lorenzini S, Giorgi M, Airo P, Cammelli D, Andreotti L, Marcolongo R, Porfirio B (2004) Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin Arthritis Rheum 33:239–248
Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, Sarles J, de Baulny HO, Touati G (2008) NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 31:81–87
McKiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drug 66:743–750
Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, Gauthier M, Lacroix J, Vanasse M, Larbrisseau A et al (1990) Neurologic crises in hereditary tyrosinaemia. N Engl J Med 322:432–437
Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In:Scriver CR, Beaudet AL, Sly WS, Valle D, Vogelstein B (eds) The metabolic and molecular bases of inherited disease (OMMBID), Chap 79, 8th edn. McGraw- Hill, New York, pp 1777–1805. http://www.ommbid.com. Modified 2002
Miyamoto BE, Kakkis ED (2011) The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis 6:49
Moser AB, Borel J, Odone A, Naidu S, Cornblath D, Sanders DB, Moser HW (1987) A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol 21:240–249
Perry MB, Suwannarat P, Furst GP, Gahl WA, Gerber LH (2006) Musculoskeletal findings and disability in alkaptonuria. J Rheumatol 33:2280–2285
Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA (2002) Natural history of alkaptonuria. N Engl J Med 347:2111–2121
Santra S, Baumann U (2008) Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother 9:1229–1236
Sassa S, Kappas A (1983) Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 71:625–634
Saunders ER, Bateson W (1902) The facts of Heredity in the light of Mendel’s discovery. Report of the Evolution Committee of the Royal Society 1:135
Saunders ER, Punnett RC, Bateson W (1905) Further experiments on inheritance in sweet peas and stocks. Proc R Soc Lond B 77:236–238
Saunders ER, Punnett RC, Bateson W (1906) Experimental studies in the physiology of heredity. Report to the Evolution Committee of the Royal Society 3:2–11
Saunders ER, Punnett RC, Bateson W (1908) Experimental studies in the physiology of heredity. Report to the Evolution Committee of the Royal Society 4:2–5
Sharma A, Jacob A, Tandon M, Kumar D (2010) Orphan drug: development trends and strategies. J Pharm Bioallied Sci 2:290–299
Srsen S, Müller CR, Fregin A, Srsnova K (2002) Alkaptonuria in Slovakia: thirty-two years of research on phenotype and genotype. Mol Genet Metab 75:353–359
Suwannarat P, O’Brien K, Perry MB, Sebring N, Bernardini I, Kaiser-KupferMI RBI, Tsilou E, Gerber LH, Gahl WA (2005) Use of nitisinone inpatients with alkaptonuria. Metabolism 54:719–728
Suzuki Y, Oda K, Yoshikawa Y, Maeda Y, Suzuki T (1999) A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. J Hum Genet 44:79–84
Tatum EL (1958) A case history in biological research. In: Nobel Lectures including presentation speeches and laureates’ biographies. Physiology or Medicine, 1942–1962. Elsevier, Amsterdam. http://nobelprize.org/nobel_prizes/medicine/laureates/1958/. Accessed 9 July 2011
Wheldale M (1915) The anthocyanin pigments of plants, 1st edn. Cambridge University Press, Cambridge
Wheldale Onslow M et al (1981) The classical period in chemical genetics: recollections of Muriel Wheldale Onslow, Robert and Gertrude Robinson and J. B. S. Haldane Rose Scott-Moncrieff. Notes and Records of the Royal Society of London 36(1):125–154
Wills R (1847) The works of W. Harvey (Transl). Sydenham Society, London, p 616
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Jean-Marie Saudubray.
Rights and permissions
Copyright information
© 2011 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Cox, T.M. (2011). Alkaptonuria: Leading to the Treasure in Exceptions. In: JIMD Reports - Case and Research Reports, 2012/2. JIMD Reports, vol 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_93
Download citation
DOI: https://doi.org/10.1007/8904_2011_93
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28095-5
Online ISBN: 978-3-642-28096-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)